Juxiang Xiao

机构：First Affiliated Hospital of Xi'an Jiaotong University

发表论文 35 篇 · 总被引 1323 次 · h-index 11

代表论文

• Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial (2023 · The Lancet Oncology · 被引 438)
• Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial (2022 · Journal of Clinical Oncology · 被引 191)
• Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2) (2022 · Nature Communications · 被引 151)
• Camrelizumab Combined with Chemotherapy Followed by Camrelizumab plus Apatinib as First-line Therapy for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (2021 · Clinical Cancer Research · 被引 118)
• Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A double‐blind randomized phase 2 trial (2021 · Cancer Medicine · 被引 117)
• Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study. (2022 · Journal of Clinical Oncology · 被引 111)